Hikma Pharmaceuticals USA Inc.
Hikma Pharmaceuticals USA Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States. Founded in 1978, Hikma has established itself as a leader in the development and manufacturing of generic and branded medications, with a strong focus on injectable products. The company operates extensively across North America, Europe, and the Middle East, providing essential healthcare solutions. Hikma's core offerings include a diverse range of injectable medicines, oral solids, and complex generics, distinguished by their commitment to quality and innovation. With a robust pipeline and a reputation for reliability, Hikma has achieved significant milestones, including strategic acquisitions that have bolstered its market position. Recognised for its dedication to patient care, Hikma Pharmaceuticals continues to make strides in enhancing access to vital medications worldwide.
DitchCarbon Score
How does Hikma Pharmaceuticals USA Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikma Pharmaceuticals USA Inc.'s score of 27 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hikma Pharmaceuticals USA Inc.'s reported carbon emissions
Hikma Pharmaceuticals USA Inc. currently does not have available carbon emissions data for the most recent year, as no specific figures have been provided. Consequently, there are no reported emissions in terms of Scope 1, 2, or 3. In the absence of concrete emissions data, it is important to note that the company has not outlined any specific reduction targets or commitments to climate initiatives. This lack of publicly available information may reflect a broader industry context where pharmaceutical companies are increasingly being called upon to disclose their environmental impact and set ambitious climate goals. As the industry evolves, it is anticipated that Hikma Pharmaceuticals USA Inc. will align with global trends towards sustainability and carbon neutrality, potentially adopting frameworks such as the Science Based Targets initiative (SBTi) in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hikma Pharmaceuticals USA Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
